A survey of psoriasis patients on biologics during COVID-19: a high-epidemic area experience - Franche Comté, France

Eur J Dermatol. 2021 Feb 1;31(1):101-103. doi: 10.1684/ejd.2020.3960.

Authors

Irène Gallais-Serezal¹, Eve Puzenat², Joséphine Moreau³, Flora Dresco², Fabien Pelletier¹, Charlée Nardin¹, François Aubin¹

Affiliations

¹ Dpt of Dermatology, University Hospital, Besançon, France, Inserm 1098 RIGHT, University of Franche Comté, Besançon, France.
² Dpt of Dermatology, University Hospital, Besançon, France.
³ Dpt of Dermatology, University Hospital, Besançon, France, Dpt of Infectious Diseases, University Hospital, Besançon, France.

No abstract available

MeSH terms

Adult
Biological Products / therapeutic use*
COVID-19 / epidemiology*
Comorbidity
Female
France / epidemiology
Humans
Male
Medication Adherence
Middle Aged
Psoriasis / drug therapy*
SARS-CoV-2
Surveys and Questionnaires
Symptom Flare Up

Substances

Biological Products